Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Atossa Genetics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,078
  • Shares Outstanding, K 2,820
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,120 K
  • 36-Month Beta 3.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.25

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.30 +5.65%
on 06/19/18
3.52 -30.97%
on 05/23/18
-1.08 (-30.77%)
since 05/22/18
3-Month
2.30 +5.65%
on 06/19/18
6.66 -63.51%
on 03/23/18
-4.23 (-63.51%)
since 03/22/18
52-Week
2.30 +5.65%
on 06/19/18
19.08 -87.26%
on 10/25/17
-3.69 (-60.29%)
since 06/22/17

Most Recent Stories

More News
Atossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men

Atossa Genetics Inc. (ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today...

ATOS : 2.43 (-3.19%)
Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board

Atossa Genetics Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions,...

ATOS : 2.43 (-3.19%)
Atossa Announces $13.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering

Atossa Genetics Inc. ("Atossa" or "the Company") announced today that the Company's previously announced rights offering ("the Rights Offering") expired on Thursday, May 24, 2018 and these rights are no...

ATOS : 2.43 (-3.19%)
Atossa Genetics Receives Positive Interim Safety Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men

Atossa Genetics Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions,...

ATOS : 2.43 (-3.19%)
Atossa Genetics Supports National Women's Health Week Lead by U.S. Department of Health and Human Services' Office on Women's Health

Atossa Genetics Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions,...

ATOS : 2.43 (-3.19%)
Atossa Genetics Regains NASDAQ Compliance

Atossa Genetics Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions,...

ATOS : 2.43 (-3.19%)
Atossa Genetics Reminds Investors of Today's Deadline to be a Shareholder of Record

- To be a shareholder of record, investors are advised to own Atossa stock by 4:00 PM ET, Monday, May 7, 2018 to account for two-day settlement

ATOS : 2.43 (-3.19%)
Atossa Genetics Forms Strategic Advisory Board to Accelerate Growth

Atossa Genetics Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions,...

ATOS : 2.43 (-3.19%)
Atossa Genetics Receives Positive Interim Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men

Atossa Genetics Inc. (ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today...

ATOS : 2.43 (-3.19%)
Atossa Genetics Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

Atossa Genetics Inc. (ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today...

ATOS : 2.43 (-3.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ATOS with:

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

2nd Resistance Point 2.61
1st Resistance Point 2.52
Last Price 2.43
1st Support Level 2.37
2nd Support Level 2.31

See More

52-Week High 19.08
Fibonacci 61.8% 12.67
Fibonacci 50% 10.69
Fibonacci 38.2% 8.71
Last Price 2.43
52-Week Low 2.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar